Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Background Clinical trials and real-world studies revealed a spectrum of response to CGRP
(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at …

Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a
favourable option for patients with migraine who experience distressful headache disability …

Background Erenumab has demonstrated effectiveness for prevention of migraine attacks,
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …

Background Real-world data are accumulating on the effectiveness, tolerability and safety of
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …

The calcitonin gene-related peptide (CGRP) is implicated in the pathogenesis of several
pain-related syndromes, including migraine. Targeting CGRP and its receptor by their …

Background and purpose Based on their pharmacological target, two classes of calcitonin‐
gene‐related peptide (CGRP) monoclonal antibodies (mAbs) have been identified …

Objective To investigate in real-life the conversion from chronic migraine (CM) to episodic
migraine (EM), specifically to EM with High-Frequency (HFEM: 8–14 monthly migraine days …

Introduction Monoclonal antibodies (mAbs) showed efficacy in migraine prevention. The aim
of this study was to check if baseline clinical parameters and cerebral blood flow (CBF) …